Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Accumulated Expenses (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Accumulated Expenses for 4 consecutive years, with $9.1 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 25.84% to $9.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.1 million through Dec 2025, down 25.84% year-over-year, with the annual reading at $9.1 million for FY2025, 25.84% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $9.1 million at Spruce Biosciences, up from $7.5 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $14.6 million in Q4 2023, with the low at $893000.0 in Q2 2022.
  • Average Accumulated Expenses over 4 years is $7.9 million, with a median of $8.7 million recorded in 2022.
  • The sharpest move saw Accumulated Expenses soared 773.75% in 2023, then plummeted 33.37% in 2024.
  • Over 4 years, Accumulated Expenses stood at $9.4 million in 2022, then soared by 55.34% to $14.6 million in 2023, then decreased by 15.55% to $12.3 million in 2024, then dropped by 25.84% to $9.1 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $9.1 million, $7.5 million, and $6.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.